1. Perlu dilakukan penelitian selanjutnya dalam jangka waktu yang lebih lama untuk melihat efek samping yang timbul dari pemberian melatonin bersamaan dengan metilprednisolon.
2. Penelitian ini hanya mengukur kuantitas atau jumlah leukosit dan limfosit.
Perlu dilakukan penelitian lebih lanjut untuk mengetahui jangka waktu pemberian melatonin yang optimal yang dapat menghambat penurunan kualitas fungsi leukosit dan limfosit.
71
xc
3. Perlu dilakukan penelitian lebih lanjut pada manusia dalam bentuk uji klinik untuk mendapatkan data yang lebih akurat tentang efektivitas melatonin dalam menghambat penurunan jumlah jumlah leukosit dan limfosit.
xci
DAFTAR PUSTAKA
Al-Hussain, S. M. 2006. The Pinealocytes of The Hman Pineal Gland:: A Light and Electron Microscopic Study. Folia Morphology. 65 (3): 181 – 7.
Baratawidjaja, K. G., Rengganis, I. 2009. Imunologi Dasar Ed. 11(Cetakan ke-2).
Jakarta: FKUI. Pages:65-199.
Barnes, P. J. 2006. Corticosteroids: the drugs to beat. European Journal of Pharmacology.533(1-3):2-14.
Boyman, O., Sprent, J. 2012. The role of interleukin-2 during homeostasis and activation of the immune system. Nature Reviews Immunology 12.
Buscemi, N., Vandermeer, B., Pandya, R., Hooton, N., Tjosvold, L., Hartling, L., Baker, G., Vohra, S., and Klassen, T. 2004. Melatonin for Treatment Sleep Disorders : Summary of Evidence Report/Technology Assessment. Agency for Healthcare Research and Quality. Number 108.
Carrillo-Vico, A., Garcia-Maurino, S., Calvo, J., Guerrero, J.M., 2003. Melatonin Counteracts The Inhibitory Effect Of PGE2 On IL-2 Production In Human Lymphocytes Via Its MT1 Membrane Receptor. Federation of American Societies for Experimental Biology. 17 : 6 755-757.
Carrillo-Vico, A., Lardone, P., Álvarez-Sánchez, N., Rodríguez-Rodríguez, A., Guerrero, J.M., 2013. Melatonin: Buffering the Immune System.
International Journal of Molecular Sciences. 14: 8638-8683.
Chiossone, L., Vitale C., Cottalasso, F., Moretti, S., Azzarone, B., Moretta, L., Mingari, M. 2007. Molecular analysis of methylprednisolone-mediated inhibition of NK-cell fungtion: evidence for different suscentibility of IL-2 versus IL-15-activated NK cell. Blood: Immunobiology. The American Society of Hematology.
Coutinho, A., Chapman, K. E. 2010. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.
Molecular and Cellular Endocrinolog. Ireland: Elsevier. 335:2-13.
Da-Silva-Ferreira, C. D. S., Maganhin, C., Dos-Santos-Simoes, R., Girao, B. C., Baracat, E. C., Soares, J.A. 2010. Melatonin: Cell Death modulator. Revista da Associação Médica Brasileira. 56. No.6.
773
xcii
Davis, T. E., Kis-Toth, K., Szanto, A., Tsukos, G. C. 2013. Glucocrticoid Suppress T Cell Fungtion by upregulating microRNA 98. Arthritis and Rheumatism. 65 (7):1882-1890.
Doghramji, K. 2007. Melatonin and Its Receptors: A New Class of Sleep-Promoting Agents. Journal of Clinical Sleep Medicine. [cite 2015 Oktober 20]
Available from: http:// www .ncbi. nlm.nih.gov/pmc/articles/ PMC1978320/
pdf/jcsm.3 .5.s17.pdf
Dubocovich, M. 2007. Melatonin receptors: Role on sleep and circadian rhythm regulation. Sleep Medicine. 8 (6) Pages: 34-42.
Espino, J., Pariente, J.A., Rodriguez A. B. 2012. Oxidative Stress and Immunosenescence: Therapeutic Effects of Melatonin. [cited 2015 Oktober.
20]. Available from: URL http://www.hindawi.com/
journals/omcl/2012/670294/
Federer, W. 2008. Statistic and Scociety, Data Collection and Interpretation. Edisi 2.
New York: Marcel Dekker.
Flaster, H., Bernhagen,J., Calandra, T., Bucala, R. 2007. The Macrophage Migration Inhibitory Factor-Glucocorticoid Dyad: Regulation of Inflammation and Immunity. Molecular Endocrinology. [cited 2015 Oktober. 25] Available from: http://press.endocrine.org/doi/abs/10.1210/me.2007-0065.
Goldmann, R., Klatz, R., 2005. Anti-Aging Desk Reference 2005 : Hormones and Pharmacological Agents. Anti-Aging Therapeutics.VII : 308 – 311.
Harrison, A. P., Pierzynowski, S.G. 2008. Biological Effects Of 2-Oxoglutarate With Particular Emphasis On The Regulation Of Protein, Mineral And Lipid Absorption/Metabolism, Muscle Performance, Kidney Function, Bone Formation And Cancerogenesis, All Viewed From A Healthy Ageing Perspective State Of The Art. [cited 2015 Oktober. 25]. Available from:
http://jpp.krakow.pl/journal/archive/08_08_s1/articles/04_article.html.
Kostoglou-Athanassiou, I. 2013. Therapeutic Applications of Melatonin. Therapeutic Advances in Endocrinology and Metabolism.4(1) 13–24.
Kresno, S. B. 2013. Imunologi: Diagnosis dan Prosedur Laboratorium. Edisi V.
Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
xciii
Lynch, H. E., Golberg, G.L., Chidgey, A., Van-den-Brink, M. R. M., Boyd, R., Sempowski. G. D. 2009. Thymic involution and reconstitution. Trends In Immunology. 30(7): 366-373.
Manus, W.C. 2016. Perbandingan Dosis Melatonin Menghambat Penurunan Jumlah Limfosit dan Leukosit pada Pemberian Metilprednisolon. Denpasar.
Universitas Udayana. (Unpublished)
Moreira, L. M., Behling, B., Rodrigues, R., Costa, J., Souza-Soares., L.,A. Spirulina as a Protein Source in The Nutritional Recovery Of Wistar Rats.
International Journal of Brazilian Archives Of Biology And Technology.
56(3):447-456.
Ozturk, G., Coskun, S., Erbas, D., Hasanoglu, E. 2000. The Effect of Melatonin on Liver Superoxide Dismutase, Serum Nitrate, and Thyroid Hormone Level.
The Japanese Joural of Physiology. 50(1): 149 – 53.
Pandi-Perumal, S. R., Cardinali, D.P. 2007. Melatonin: From Molecules to Therapy.
New York: Nova Science Publisher, Inc.
Pandi-Perumal, S. R., Srinivasan, V, Maestroni, G. J. M, Cardinali, D. P., Poeggeler, B., Hardeland, R. 2006. Melatonin Nature’s most versatile biological signal?
Federation of European Biochemical Societies Journal. 273 : 2813-2838.
Pangkahila, W. 2011. Anti Aging: Tetap Muda dan Sehat. Jakarta: Penerbit Buku Kompas.
Pangkahila, W., Wong, L. 2015. Evidence Based Antiaging Medicine Hormone Replacement Therapy. Jakarta:TLC Publisher.
Perreti, M., D'Acquisto, F. 2009. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation, Nature Reviews Immunology. 9:62-70.
Pocock, S. 2008. Clinical Trial: A Practical Approach. Chichester: John Walley &
Son. Pg: 127-128.
Ponnappan, S., Ponnappan, U. 2011. Aging and Immune Function: Molecular Mechanisms to Interventions. [cite 2015 oct.21] Available from: URL:
http://www.ncbi.nlm.nih.gov/pubmed/20812785
Rhen, T., Cidlowski, J. A. 2005. Antinflammatory Action of Glucocorticoids-New Mechanisms for Old Drugs. New England Journal Medicine. 353:1711- 1723.
xciv
Salucci, S., Burattini, S., Battistelli, M., Baldassarri, V., Curzi, D., Valmori, A., Falcieri, E. 2013. Melatonin Prevents Chemical-Induced Haemopoietic Cell Death International Journal of Molecular Sciences. 15: 6625-6640.
Santoso, M. I. E. 2011. Buku Ajar Etik Penelitian Kesehatan. Malang: UB Press.
Schmidt, S., Rainer, J., Ploner, C., Presul, E., Rimi, S., Kofler R. 2004.
Glucocorticoid-induce apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death and Differenciation. Nature Publishing Group. 11, S45-S55.
Sharnam, E. H., Bondy, S., Sharman, K.G., Lahiri, D., Cotman, C.W., Perreau, V.M.2007. Effect of Melatonin and Age on gene expression in mouse CNS using Microarray Analysis. Neurochemistry International. 50(2): 336-344.
Sinha, A., Bagga, A. 2008. Pulse Steroid Therapy. Indian Journal of Pediatric. New Delhi. 75:1057-1066.
Slominski R. M., Reiter, R. J., Schlabritz-Loutsevitch , N., Ostrom, R. S., Slominski, A. T. 2012. Melatonin membrane receptors in peripheral tissues:
Distribution and functions. Molecular and Cellular Endocrinology. 4;
351(2): 152–166.
Smith, J. B., Mangkoewidjojo, S. 1988. Pemeliharaan Pembiakan dan Penggunaan Hewan Percobaan Di Daerah Tropis. Jakarta: UI Press.
Solana, R., Pawelec, G., Tarazona, R. 2006. Aging and Innate Immunity.Immunity.
24, 491–494.
Song, J., Kang, S. M., Lee, K. M., Lee, J.E. 2015. The Protective Effect of Melatonin on Neural Stem Cell against LPS-Induced Inflamation. Hindawi Publishing Corporation Bio Med Research Internationa. [cite 2015 Oktober. 20]
Available from: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4331478/
Srinivasan, V., Maestroni, G., Cardinali, D., Esquifino, A., Perumal, S.R., Miller, S.
C. 2005. Melatonin, Immune Function And Aging. [cited 2015 September.
12] Available from: http://www.immunityageing.com/ content/2/1/17
Sukumaran, S., Lepist, E., Dubois, D., Almon, R. R., Jusko, W.J. 2012.
Pharmacokinetic/vpharmacodynamics Modeling of Methylprednisolon Effect on iNOS mRNA Ekspression and NO during LPS-induced Inflamation in Rats. Pharmaceutical Research. 29 (8);2060-2069.
xcv
Szczepanik, M. 2007. Melatonin And Its Influence On Immune System. [Cited 2015 November. 18] Available From:Http://Jpp.Krakow.Pl/Journal/Archive/
12_07_S6/Articles/09_Article.Html
Tan, D. X., Manchester L. C., Terron M. P., Flores L.J., Reiter R. J. 2007. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and reactive-nitrogen species?. Journal of Pineal Research.
2007b;42:28–42.
Torres, R., da Silva Torres, L., Laste, G., Beatriz, M., Ferreira, C., Cardoso, P., Belló-Klein. A. 2014. Effects of acute and chronic administration of methylprednisolone on oxidative stress in rat lungs. Jornal Brasileiro de Pneumologia .40.
Winarsi, H. 2010. Antioksidan Alami & Radikal Bebas. Potensi dan Aplikasinya dalam Kesehatan. Cetakan ke-4. Yogyakarta : Penerbit Kanisius. hal : 12- 15,19,29-36,86-106.
Yonei, Y., Hattori, A., Tsutsui, K., Okawa, M., Ishizuka, B. 2010. Effect of Melatonin: Basics Studies and Clinical Applications. Anti-Aging Medicine.
7(7) : 85-91.
Yu, H. S., Reiter, R. 1992. Melatonin: Biosynthesis, Physiological Effects, and Clinical Application. USA: Library of Congress.
Zen, M., Canova, M., Campana, C., Bettio, S., Nalotto, L., Rampudda, M., Ramonda, R., Iaccarino, L., Dori, A. 2011. The Kaleidoscope Of Glucorticoid Effects On Immune System. Autoimmunity Reviews.
Ireland:Elsevier. 5: 305–310.
Zhang, Y., Cook, A., Kim, J., Baranov, S.V., Jiang, J., Smith, K., Cormier, K., Bennett, E., Friedlander, R.M. 2013. Melatonin Inhibits The Caspase- 1/Cytochrome C/Caspase-3 Cell Death Pathway, Inhibits MT1 Receptor Loss And Delays Disease Progression In A Mouse Model Of Amyotrophic Lateral Sclerosis. Neurobiology of Disease. 55:26-35.
xcvi Lampiran 1. Ethical Clearance
xcvii Lampiran 2. Hasil Penelitian Pendahuluan
Penentuan Dosis Metilprednisolon
4 mg 4mg
pre 1 2 pre 1 2
Leukosit 8.6 7.97 7.81 11.8 11.13 10.28 Limfosit 7.3 4.45 5.29 7.59 5.17 4.32
% limfosit 85 55.8 67.7 64.5 46.5 42
8mg 8mg
pre 1 2 pre 1 2
Leukosit 7.8 11.5 4.57 8.62 11.17 7.76 Limfosit 5.9 5.35 2.97 5.93 5.88 3.46
%
limfosit 77 46.7 65 68.8 52.6 44.6
16 mg 16 mg
pre 1 2 pre 1 2
Leukosit 15 6.38 8.9 7.2 6.81 6.24 Limfosit 7.9 4.38 4.74 5.54 3.57 3.09
% limfosit 53 68.7 53.3 76.9 52.4 42.5
Keterangan:
Pre= pre test
1= post test 1 minggu 2=post test 2 minggu
xcviii Penentuan Dosis Melatonin
Jenis Pemeriksaan Metilprednisolon 8 mg+melatonin 3 mg
1A0 1AP 2A0 2AP 3AO 3AP
Total Leukosit
(x103) 11.16 7.26 11.13 10.2 7.46 6.32
Limfosit (x103) 7.66 4.74 7.89 8.08 5.65 3.41
% limfosit 68.80% 65.30% 70.9 76.60% 75.70% 54.00%
Jenis pemeriksaan Metilprednisolon 8mg+Plasebo
2aPre 2aPost 2bPre 2bPost 2cPre 2cPost Tota
Leukosit(x103) 7.76 4.57 8.62 7.76 7.15 18.2
Limfosit(x103) 5.94 2.97 5.93 3.46 4.75 6.24
% limfosit 76.55% 65% 68.80% 44.60% 66.40% 19.20%
Jenis Pemeriksaan metilprednisolon 8 mg+mealtonin 10 mg
7C0 7cp 8C0 8cp 9C0 9cp
Total Leukosit
(x103) 7.73 6.76 7.99 6.88 10.12 6.84
Limfosit (x103) 5.58 4.39 6.02 4.41 8.33 3.94
limfosit (%) 72.20% 64.90% 75.40% 64.10% 82.30% 57.60%
xcix
Perbandinan Jumlah Leukosit dan Limfosit Pada Pemberian Dosis Melatonin Oral 3 Mg Dan Melatonin 10 Mg
Leukosit (x103/L darah) Limfosit (x103/L darah)
Keterangan:
MP = Metilprednisolon Mel = Melatonin
No
MP+
Mel 3 mg
MP+
Mel 10 mg
MP+
Aquadest
1 10.6 5.94 8.77
2 9.41 8.5 3.38
3 9.44 3.17 7.76
4 8.06 6.84 9.69
5 4.06 7.45 8.39
6 8.37 6.33 10.47
7 8.47 5.63 5.27
8 6.57 4.07 6.04
9 12.69 2.88 5.91
10 7.65 3.89 4.98
11 7.09 4.11 6.55
12 9.81 6.76 5.06
13 7.26 9 8
14 10.2 6.07 6.42
15 6.32 4.32 6.07
16 7.9 5.64 4.57
No
MP+
Mel 3 mg
MP+
Mel 10 mg
MP+
Aquadest
1 10.6 5.94 8.77
2 9.41 8.5 3.38
3 9.44 3.17 7.76
4 8.06 6.84 9.69
5 4.06 7.45 8.39
6 8.37 6.33 10.47
7 8.47 5.63 5.27
8 6.57 4.07 6.04
9 12.69 2.88 5.91
10 7.65 3.89 4.98
11 7.09 4.11 6.55
12 9.81 6.76 5.06
13 7.26 9 8
14 10.2 6.07 6.42
15 6.32 4.32 6.07
16 7.9 5.64 4.57
c
Lampiran 3. Hasil Pemeriksaan Laboratorium Jumlah Leukosit dan Limfosit Kelompok Ulangan Leukosit Limfosit
Kontrol
1 8.77 5.59
2 3.38 1.8
3 7.76 3.46
4 9.69 4.41
5 8.39 4.73
6 10.47 1.43
7 5.27 2.01
8 6.04 2.93
9 5.91 3.66
10 4.98 2.88
11 6.55 1.62
12 5.06 1.36
13 8 4.96
14 6.42 3.59
15 6.07 2.1
16 4.57 2.97
Perlakuan
1 10.6 4.24
2 9.41 6.28
3 9.44 5.31
4 8.06 3.71
5 4.06 1.52
6 8.37 4.65
7 8.47 5.6
8 6.57 4.49
9 12.69 7.87
10 7.65 4.71
11 7.09 4.67
12 9.81 4.89
13 7.26 4.74
14 10.2 8.08
15 6.32 3.41
16 7.9 5.03
ci Lampiran 4. Analisis Deskriptif
Report
Kelompok Perlakuan
Total Leukosit
(x10^3) Limfosit (x10^3)
Plasebo Mean 6.7081 3.0938
N 16 16
Std. Deviation 1.96496 1.33403
Maximum 10.47 5.59
Minimum 3.38 1.36
Perlakuan Mean 8.3688 4.9500
N 16 16
Std. Deviation 2.01691 1.57722
Maximum 12.69 8.08
Minimum 4.06 1.52
Total Mean 7.5384 4.0219
N 32 32
Std. Deviation 2.13267 1.71872
Maximum 12.69 8.08
Minimum 3.38 1.36
Lampiran 5. Uji Normalitas Data
cii
Test of Homogeneity of Variance
Levene Statistic df1 df2 Sig.
Limfosit (x10^3) Based on Mean .010 1 30 .919
Based on Median .022 1 30 .882
Based on Median and with
adjusted df .022 1 25.277 .883
Based on trimmed mean .005 1 30 .942
Total Leukosit (x10^3) Based on Mean .057 1 30 .814
Based on Median .009 1 30 .924
Based on Median and with
adjusted df .009 1 29.940 .924
Based on trimmed mean .049 1 30 .825
Tests of Normality
Kelompok Perlakuan
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Limfosit (x10^3) Plasebo .147 16 .200* .942 16 .371
Perlakuan .167 16 .200* .922 16 .184
Total Leukosit (x10^3) Plasebo .157 16 .200* .968 16 .811
Perlakuan .105 16 .200* .983 16 .985
a. Lilliefors Significance Correction
*. This is a lower bound of the true significance.
Lampiran 6. Uji Homogenitas
ciii
Test of Homogeneity of Variance
Levene Statistic df1 df2 Sig.
Limfosit (x10^3) Based on Mean .010 1 30 .919
Based on Median .022 1 30 .882
Based on Median and with
adjusted df .022 1 25.277 .883
Based on trimmed mean .005 1 30 .942
Total Leukosit (x10^3) Based on Mean .057 1 30 .814
Based on Median .009 1 30 .924
Based on Median and with
adjusted df .009 1 29.940 .924
Based on trimmed mean .049 1 30 .825
Lampiran 7 . Uji Komparasi
civ
Independent Samples Test
Levene's Test for Equality of
Variances t-test for Equality of Means
F Sig. T df
Sig.
(2- tailed)
Mean Difference
Std. Error Differenc
e
95% Confidence Interval of the
Difference Lower Upper Leukosit (x10^3) Equal
variances assumed
.057 .814 -2.359 30 .025 -1.66063 .70396 -3.09831 -.22294
Equal variances not assumed
-2.359 29.980 .025 -1.66063 .70396 -3.09835 -.22290
Limfosit (x10^3) Equal variances assumed
.010 .919 -3.594 30 .001 -1.85625 .51643 -2.91095 -.80155
Equal variances not assumed
-3.594 29.196 .001 -1.85625 .51643 -2.91217 -.80033